sábado, 29 de enero de 2011
The clinical utility of testicular cancer risk loc... [Genome Med. 2011] - PubMed result
Genome Med. 2011 Jan 21;3(1):1. [Epub ahead of print]
The clinical utility of testicular cancer risk loci.
Kratz CP, Bratslavsky G, Shi J.
Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20852, USA. kratzcp@mail.nih.gov.
Abstract
ABSTRACT: Three recent genome-wide association studies of testicular germ cell tumors have uncovered predisposition alleles in or near several genes, including KITLG, BAK1, SPRY4, TERT, ATF7IP, and DMRT1. The calculated per-allele odds ratio for variants in the region of KITLG is the highest reported for any malignancy so far. These findings are in agreement with epidemiological data indicating that testicular cancer has a higher heritability than most other cancers. Here, we discuss the question of whether the newly identified risk polymorphisms can be used to guide patient care.
PMID: 21255381 [PubMed - as supplied by publisher]
The clinical utility of testicular cancer risk loc... [Genome Med. 2011] - PubMed result
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario